Aspergillosis - Pipeline Review, H2 2017

  • ID: 4426937
  • Drug Pipelines
  • 108 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Astellas Pharma Inc
  • Cidara Therapeutics Inc
  • Hsiri Therapeutics LLC
  • Merck & Co Inc
  • Novabiotics Ltd
  • Pulmocide Ltd
  • MORE
Aspergillosis - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Aspergillosis - Pipeline Review, H2 2017, provides an overview of the Aspergillosis (Infectious Disease) pipeline landscape.

Aspergillosis is an infection or allergic response due to the Aspergillus fungus. Symptoms include cough, fever, headaches, general ill feeling (malaise), weight loss and chest pain. The predisposing factors include weakened immune system, low white blood cell level, asthma and long-term corticosteroid therapy. Treatment includes oral corticosteroids, antifungal and surgery.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Aspergillosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Aspergillosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Aspergillosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Aspergillosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical, Discovery and Unknown stages are 2, 5, 19, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 3 molecules, respectively.

Aspergillosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Aspergillosis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Aspergillosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Aspergillosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Aspergillosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Aspergillosis (Infectious Disease).
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Aspergillosis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Aspergillosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Astellas Pharma Inc
  • Cidara Therapeutics Inc
  • Hsiri Therapeutics LLC
  • Merck & Co Inc
  • Novabiotics Ltd
  • Pulmocide Ltd
  • MORE
Introduction

Aspergillosis - Overview

Aspergillosis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Aspergillosis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Aspergillosis - Companies Involved in Therapeutics Development

Amplyx Pharmaceuticals Inc

Astellas Pharma Inc

Biosergen AS

Cidara Therapeutics Inc

F2G Ltd

Hsiri Therapeutics LLC

iCo Therapeutics Inc.

Matinas BioPharma Holdings Inc

Merck & Co Inc

Nanomerics Ltd

Novabiotics Ltd

Pulmatrix Inc

Pulmocide Ltd

Scynexis Inc

Sealife PHARMA GMBH

Sigma-Tau SpA

Viamet Pharmaceuticals Inc

Vical Inc

Visterra Inc

Aspergillosis - Drug Profiles

amphotericin B - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

amphotericin B - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

amphotericin B - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

amphotericin B - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Amphotericin B sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APX-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APX-001A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-9726 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aspergillus fumigatus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BSG-005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-016 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CD-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

celastrol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellullar Immunotherapy for Viral Infections and Fungal Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

F-901318 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

itraconazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDN-0018 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NP-339 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PC-945 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

posaconazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PTX-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SCY-078 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SLP-0901 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SLP-0904 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Aspergillosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Fungal Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Fungal Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Invasive Aspergillosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Glucosylceramide for Fungal Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VIS-FNG - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VL-2397 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

voriconazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VT-1598 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aspergillosis - Dormant Projects

Aspergillosis - Discontinued Products

Aspergillosis - Product Development Milestones

Featured News & Press Releases

Oct 31, 2017: Pulmatrix Presents at the North American Cystic Fibrosis Conference

Oct 30, 2017: Pulmatrix Appoints Dr. James Roach as Chief Medical Officer

Oct 05, 2017: Researchers help develop new antifungal drug

Oct 05, 2017: SCYNEXIS Presents New Data Further Supporting SCY-078 as a Potential Treatment for Aspergillus and Candida Infections at IDWeek 2017

Oct 02, 2017: Vical Announces that its Antifungal VL-2397 is Eligible for Limited Use Indication Approval by FDA Based on a Single Phase 2 Efficacy Trial

Sep 28, 2017: Vical to Present at IDWeek and the 8th Trends in Medical Mycology Conferences

Sep 27, 2017: SCYNEXIS to Present Data on Lead Antifungal Candidate SCY-078 at IDWeek 2017

Sep 05, 2017: Pulmatrix Receives Award from Cystic Fibrosis Foundation Therapeutics to Support Development of PUR1900 for the Treatment of Pulmonary Fungal Infections

Jun 05, 2017: Eight Presentations at ASM Microbe 2017 Further Highlight the Strong Antifungal Effect and Promising Safety Profile of Lead Anti-Infective Candidate SCY-078

Jun 05, 2017: Vical Presents Phase 1 VL-2397 Data at the June ASM Microbe 2017 Meeting Supporting Advancement to Phase

May 30, 2017: Cidara Therapeutics Announces Presentations at ASM Microbe 2017 and the 22nd Congress of the European Hematology Association

May 24, 2017: Eight SCY-078 Data Presentations at ASM Microbe 2017 Confirm Potential of SCYNEXIS' Lead Agent to Combat Serious and Life-threatening Fungal Infections

May 23, 2017: Vical to Present VL-2397 Data at the June ASM Microbe 2017 Meeting

May 02, 2017: Vical Highlights Successful Outcome of Phase 1 Trial of VL-2397 Novel Antifungal During its Research and Development Day

Apr 25, 2017: Cidara Therapeutics Announces Promotion of Taylor Sandison, M.D., M.P.H., to Chief Medical Officer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Aspergillosis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Aspergillosis - Pipeline by Amplyx Pharmaceuticals Inc, H2 2017

Aspergillosis - Pipeline by Astellas Pharma Inc, H2 2017

Aspergillosis - Pipeline by Biosergen AS, H2 2017

Aspergillosis - Pipeline by Cidara Therapeutics Inc, H2 2017

Aspergillosis - Pipeline by F2G Ltd, H2 2017

Aspergillosis - Pipeline by Hsiri Therapeutics LLC, H2 2017

Aspergillosis - Pipeline by iCo Therapeutics Inc., H2 2017

Aspergillosis - Pipeline by Matinas BioPharma Holdings Inc, H2 2017

Aspergillosis - Pipeline by Merck & Co Inc, H2 2017

Aspergillosis - Pipeline by Nanomerics Ltd, H2 2017

Aspergillosis - Pipeline by Novabiotics Ltd, H2 2017

Aspergillosis - Pipeline by Pulmatrix Inc, H2 2017

Aspergillosis - Pipeline by Pulmocide Ltd, H2 2017

Aspergillosis - Pipeline by Scynexis Inc, H2 2017

Aspergillosis - Pipeline by Sealife PHARMA GMBH, H2 2017

Aspergillosis - Pipeline by Sigma-Tau SpA, H2 2017

Aspergillosis - Pipeline by Viamet Pharmaceuticals Inc, H2 2017

Aspergillosis - Pipeline by Vical Inc, H2 2017

Aspergillosis - Pipeline by Visterra Inc, H2 2017

Aspergillosis - Dormant Projects, H2 2017

Aspergillosis - Discontinued Products, H2 2017

List of Figures

Number of Products under Development for Aspergillosis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Amplyx Pharmaceuticals Inc
  • Astellas Pharma Inc
  • Biosergen AS
  • Cidara Therapeutics Inc
  • F2G Ltd
  • Hsiri Therapeutics LLC
  • iCo Therapeutics Inc.
  • Matinas BioPharma Holdings Inc
  • Merck & Co Inc
  • Nanomerics Ltd
  • Novabiotics Ltd
  • Pulmatrix Inc
  • Pulmocide Ltd
  • Scynexis Inc
  • Sealife PHARMA GMBH
  • Sigma-Tau SpA
  • Viamet Pharmaceuticals Inc
  • Vical Inc
  • Visterra Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll